A Phase III Randomised comparison of Gemcitabine/Carboplatin with Cisplatin/Etoposide in Small Cell Lung Cancer
Phase 3
Completed
- Conditions
- ung (small cell) cancerCancerLung (small cell)
- Registration Number
- ISRCTN39679215
- Lead Sponsor
- CRI CSG and London Lung Cancer Group (UK)
- Brief Summary
2001 Results article in http://www.ncbi.nlm.nih.gov/pubmed/11510029 results
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 241
Inclusion Criteria
1. Histologically or cytologically proven small cell anaplastic carcinoma of the lung
2. Extensive stage disease or limited stage but locally advanced or limited stage with poor prognostic factors
3. Measurable or evaluable disease
4. Adequate renal function for chemotherapy
5. Age 18 years or above
6. Adequate contraception for women of child bearing potential
7. Written informed consent
Exclusion Criteria
Not provided at time of registration
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method ot provided at time of registration
- Secondary Outcome Measures
Name Time Method ot provided at time of registration